MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells

Kyoung Hyun Kim^{1,2}, Robert Burghardt³, Rola Barhoumi³, Syng-ook Lee², Xinyi Liu⁴ and Stephen Safe^{1,2}

¹Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, Texas 77843-4466, USA

²Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas 77030, USA

Departments of ³Veterinary Integrative Biosciences and ⁴Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, USA

(Correspondence should be addressed to S Safe at Department of Veterinary Physiology and Pharmacology, Texas A&M University; Email: ssafe@cvm.tamu.edu)

Abstract

Murine double minute clone 2 (MDM2) is a multifunctional protein, which modulates nuclear receptor-mediated transactivation. In this study, we show that MDM2 significantly enhanced estrogen receptor α (ER α) and ER α /specificity protein-mediated transactivation in MCF-7 and ZR-75 breast cancer cells. This was demonstrated by both MDM2 overexpression and knockdown experiments by RNA interference. ER α interacted with wild-type MDM2 and deletion mutants of MDM2 containing amino acids 1–342 (C-terminal deletion) and 134–490 (N-terminal deletion), but not 134–342. In contrast, only wild-type but not mutant MDM2 enhanced ER α -mediated transactivation. Protein–protein interactions *in vitro* were 17 β -estradiol (E₂) independent, whereas fluorescent resonance energy transfer experiments in living cells showed that E₂ enhanced ER α –MDM2 interactions. Subsequent RNA interference and mammalian two-hybrid experiments suggested that MDM2 did not directly interact with endogenous coactivators such as the steroid receptor coactivators but played a role in enhancing ER α -mediating gene expression and estrogen responsiveness through interactions with ER α .

Journal of Molecular Endocrinology (2011) **46**, 67–79

Introduction

Murine double minute clone 2 (MDM2) was initially cloned from a transformed 3T3 cell line, and later identified as a p53-interacting protein (Cahilly-Snyder *et al.* 1987, Fakharzadeh *et al.* 1991, Momand *et al.* 1992). It was subsequently shown that overexpression of MDM2 resulted in cell transformation and oncogenicity and this was due, in part, to suppression of the tumor suppressor gene *p53*. The complex interrelationships between MDM2 and p53 have been extensively investigated (Levav-Cohen *et al.* 2005, Brooks & Gu 2006). MDM2 exhibits E3-ubiquitin ligase activity, which increases ubiquitination of p53 and, in combination with other factors, the resulting proteasome-dependent degradation of p53 decreases expression of this tumor suppressor gene under nonstressed conditions (Ashcroft *et al.* 1999, Kubbutat *et al.* 1999). The role of MDM2 in regulating p53 expression is also apparent in transgenic mice where MDM2 knockout animals exhibit embryolethality, which is reversed by inactivation of p53 (Jones *et al.* 1995, Montes de Oca Luna *et al.* 1995, de Rozieres *et al.* 2000). Under conditions of cellular stress, the physical and functional interactions of MDM2 and p53 are inhibited, thereby allowing p53 to activate gene expression pathways, such as inhibition of cell cycle

progress and induction of apoptosis, which allow the cells to respond to stressors. The interactions between p53 and MDM2 are complex and are modified under various conditions and in a cell/tissue context-dependent manner (Brooks & Gu 2006).

Since MDM2 inhibits p53 function as a tumor suppressor gene, it is not surprising that expression of MDM2 plays a role in cancer and in cancer prognosis (Levav-Cohen *et al.* 2005). Overexpression of MDM2 is frequently observed in many different cancers; however, the prognosis for patients in which MDM2 levels are high is dependent on multiple factors including the type of tumor and its origin. For example, MDM2 overexpression through gene amplification in gliomas predicts poor survival (Korkolopoulou *et al.* 1997, Rainov *et al.* 1997, Schiebe *et al.* 2000), whereas overexpression through gene amplification in breast cancer is observed only in estrogen receptor (ER)-positive tumors for which there is a good prognosis for survival (Bueso-Ramos *et al.* 1996, Lukas *et al.* 2001, Hori *et al.* 2002). The variability of MDM2 as a prognostic indicator for cancer survival is complex and may be due to interactions with other unknown factors.

A number of p53-independent functions of MDM2 have been identified and show that this protein can modify different signaling pathways. MDM2 interacts

with and inhibits the function of retinoblastoma (Rb) protein and other Rb family members (Hsieh *et al.* 1999) and this affects E2F1-DP1-mediated responses (Martin *et al.* 1995) and also enhances the transcriptional activation of cyclin A (Leveillard & Wasylyk 1997). MDM2 also modulates ligand-dependent activation of several steroid hormone receptors including the glucocorticoid receptor, androgen receptor, and ER (Liu *et al.* 2000, Saji *et al.* 2001, Sengupta & Wasylyk 2004). MDM2 overexpression in MCF-7 human breast cancer cells enhances their estrogen-dependent growth and, in p53-deficient Saos-2 osteosarcoma cells and MCF-7 cells, MDM2 enhances 17 β -estradiol (E₂)-dependent activation of a construct containing an estrogen response element (ERE) insert (Saji *et al.* 2001).

This study shows by RNA interference that MDM2 enhances E₂-dependent growth and transactivation in breast cancer cells using constructs containing three tandem EREs or GC-rich motifs (pSP1₃) activated by ER α or ER α /SP1 respectively. MDM2 overexpression also coactivates ER α and ER α /SP1, and the results suggest that the coactivation response is primarily through direct interactions of MDM2 with ER α and MDM2-dependent enhanced interactions of ER α with coactivators.

Materials and methods

Cell lines, chemicals, and biochemicals

The ZR-75 (ZR-75.1), MCF-7, and T47D human breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI 1640 or DMEM (Sigma) supplemented with 5 or 10% FBS and the medium was further supplemented with antibiotic/antimycotic solution (Sigma). Prior to transfection, RPMI or DMEM medium was replaced by DMEM/F-12 (Sigma) supplemented with charcoal-stripped 10% FBS. Cells were maintained at 37 °C with a humidified CO₂/air (5:95) mixture. Small inhibitory RNA (siRNA) duplexes for MDM2 (siMDM2), p53 (sip53), luciferase (siGL2), and the scrambled siRNA (siCT) were purchased either from Ambion (Austin, TX, USA) or Sigma-Aldrich. The sequence for siGL2: 5'-CGU ACG CGG AAU ACU UCG ATT-3'; for siMDM2: 5'-GAA CAA GAG ACC CTG GTT A-3'; for sip53: 5'-GAG GUU GGC UCU GAC UGU A-3'; for scrambled RNA (siCT): 5'-ACU CUA UCU GCA CGC UGA CTT-3'.

Plasmids and cloning

pERE₃, pSP1₃, pCAD, and pE2F1 were previously generated in our laboratory. pcDNA-MDM2 (490 aa) was kindly provided by Dr Lane (University of Dundee, UK). The MDM2 deletion mutants (135–490 aa, 135–342

aa, and 1–342 aa) were generated by cloning MDM2 deletion mutant amplified PCR products into EcoRI/XhoI sites of pcDNA3.1His plasmid. MDM2 deletion mutants were generated by PCR using following primer sets: 1–342 aa: (F) 5'-GAA TTC ATG TGC AAT ACC AAC ATG TC-3', (R) 5'-CTC GAG TTT TTC AGA GAT TTC CAC-3'; 134–490 aa: (F) 5'-GAATTC CCT TTG CAA GCG CCA CCA G-3', (R) 5'-CTC GAG CTA GTT GAA GTA AGT TAG CAC-3'; 135–342 aa: (F) 5'-GAA TTC CCT TTG CAA GCG CCA CCA G-3', (R) 5'-CTC GAG TTT TTC AGA GAT TTC CAC-3'. These generated Xpress-tagged expression plasmids were also used for *in vitro* coimmunoprecipitation assays. pMDM2 and VP-MDM2 expression plasmids were generated by PCR amplification of MDM2 wild-type and cloned into EcoRI and HindIII sites of pM and VP16 vectors (Clontech). For ECFP-MDM2 vector generation, the amplified MDM2 PCR product was digested with EcoRI and XhoI, and cloned into CFP-C1 vector (Clontech). The GAL4-coactivator fusion plasmids pMSRC-1, pMGRIPwt, and pMAIB-1 were kindly provided by Dr Shigeaki Kato (University of Tokyo, Tokyo, Japan), and pMGRIP(LXXLL) (fused to the yeast GAL4 DBD) was obtained from Dr Donald McDonnell (Duke University, Durham, NC, USA).

Transient transfection assays

The cells were seeded into 12-well plates in phenol-free DMEM/F-12 supplemented with 5% charcoal-stripped FBS. After 24 h, cells were transfected by lipofectamine 2000 reagent (Invitrogen) with 250 ng of an appropriate reporter plasmid (pERE₃, pSP1₃, pCAD, pE2F1, or GAL4-luciferase), 50 ng of a CMV β -galactosidase expression plasmid, and other appropriate expression plasmids (125 ng/well) (ER α , MDM2 wild-type and mutants (1–342 aa, 134–490 aa, and 135–342 aa)), pMER α , pMDM2, VP-ER α , or VP-MDM2. Empty vectors or nonspecific (siCT) oligonucleotides were used as controls in all transfection experiments. After transfection for 24 h, cells were treated with Me₂SO or 10 nmol/l E₂ with 5% stripped serum media for 24 h. In cells transfected with siRNA(s), E₂ was added after 36–48 h for accomplishing efficient knockdown of target gene. Cells were then harvested, and luciferase activity (relative to β -galactosidase activity) was determined. Normalized luciferase values were obtained by dividing the luciferase by the β -galactosidase activities for a given sample. The results are expressed as means $\pm$ S.E.M. for at least three separate experiments for each treatment group.

In vitro coimmunoprecipitation assay

[³⁵S]ER α , [³⁵S]MDM2wt, [³⁵S]MDM2(1–342 aa), [³⁵S]MDM2 (134–342 aa), or [³⁵S]MDM2 (134–490 aa) were *in vitro* translated using the T7 QuikCoupled

Transcription Translation System (Promega Corp.). MDM2 wild-type and all mutants were Xpress tagged. [^{35}S]ER α (1 μl) and ^{35}S -labeled MDM2 wild-type or deletion mutant protein (0.5 μl) were coincubated in coimmunoprecipitation buffer (sterilized PBS + 0.01% IGEPAL CA630) with E_2 to give a final concentration of 100 nM E_2 . After incubation for 1 h at 4 °C, 25 μl of 50% slurry of protein G-sepharose beads (Amersham Biosciences) were added to the incubation solution, followed by incubation for 2 h on a rocker at 4 °C. Samples were then centrifuged and washed, the final pellet was boiled in 30 μl of 2 $\times$ SDS sample buffer, and proteins were separated on a 8% SDS-PAGE and visualized by autoradiography.

Western blot analysis

Depletion of MDM2 protein was determined, 48 h after transfection with siRNA for MDM2, breast cancer cells were harvested with RIPA lysis buffer (1 $\times$ PBS, 1% Nonidet P-40 or Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mg/ml phenylmethylsulfonyl fluoride in isopropanol, aprotinin, and 100 nM sodium orthovanadate), and equal amounts of protein from each group were boiled with sample buffer and loaded onto 8% SDS-polyacrylamide gel. The membrane was blocked and probed with primary antibodies for MDM2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) O/N at 4 °C. Membrane was visualized using the ECL detection system (PerkinElmer Life Sciences, Boston, MA, USA).

Cell proliferation assay

MCF-7 or ZR-75 cells (5×10^4 per well) were plated into 12-well plates and allowed to attach for 24 h, and then cells were transfected with either control siRNA or MDM2 siRNA. After 24 h, the medium was changed to charcoal-stripped 5% FBS DMEM medium containing either vehicle (DMSO) or estrogen (10 nM). Fresh medium was added every 48 h. Cells were then trypsinized and counted at the indicated times using a Coulter Z1 particle counter. Each experiment was performed in triplicate and the results are expressed as means $\pm$ S.E.M. for each treatment group.

Quantitative RT-PCR

RNA was harvested from T47D cells using the RNeasy mini or micro kits (Qiagen). First-strand cDNA synthesis was performed with 1 μg RNA using Reverse Transcription kit from Promega. Real-time PCR was performed using SYBR Green PCR Master Mix reagent, the ABI PRISM 7000 sequence detection system, and software (Applied Biosystems, Foster City, CA, USA).

The primer sets were for CAD: (F) 5'-ACC ACG ACA CCT GAA AGA CC-3', (R) 5'-TAC TGG TGG TGG AGG GTA GC-3'; for pS2: (F) 5'-CAC CAT GGA GAA CAG GTG A-3', (R) 5'-AGC CCT TAT TTG CAC ACT GG-3'; for cyclin D1: (F) 5'-CGA TGC CAA CCT CCT CAA CGA-3', (R) 5'-TCG CAG ACC TCC AGC ATC CA-3'; for β -actin: (F) 5'-GGG GTG TTG AAG GTC TCA AA-3'; for E2F1: (F) 5'-ATG TTT TCC TGT GCC CTG AG-3', (R) 5'-ATC TGT GGT GAG GGA TGA GG-3'.

Fluorescence resonance energy transfer analysis

The cells were grown in two-well Lab-Tek Chambered Coverglass slides (Nalge Nunc International, Rochester, NY, USA) in DME/F12 medium supplemented with 5% charcoal-stripped serum and then transfected with CFP-MDM2/YFP-ER α or CFP-SP1/YFP-ER α sets. All the procedures for measuring fluorescence resonance energy transfer (FRET) efficiency were previously described (Kim *et al.* 2005). Briefly, after transfection for 24 h, cells were put on the stage of a Bio-Rad 2000 MP microscope system (Bio-Rad Laboratories) equipped with a Nikon T#300 inverted microscope. The images were acquired between 5 and 15 min before and after the addition of 10 nM E_2 . FRET efficiency data were collected using two photon 820 nm excitation wavelength. Emission of CFP (CFP channel, donor signal) was collected using a 500DCLP dichroic and 450/80 nm filter, whereas emission of YFP (FRET channel, acceptor signal) was collected using a 528/50 nm filter. CFP-SP1/YFP-ER α set was used as positive control after E_2 treatment in this experiment. For FRET analysis, MetaMorph software version 6.0 (Universal Imaging Corp., Downingtown, PA, USA) was used and FRET signals were corrected by subtracting the background signal as well as the donor bleed through signal. At least 50 cells per treatment were analyzed by one-way ANOVA followed by Dunnett's test.

Statistical analysis

Statistical differences between different treatments were determined using Student's *t*-test or ANOVA (Fisher's protected least significant difference), and the levels of significance are shown ($P < 0.05$). The results are expressed as mean $\pm$ S.E.M. for at least three replicate determinations for each experiment.

Results

MDM2 enhances E_2 -dependent transactivation

Previous studies showed that E_2 responsiveness was enhanced in MCF-7 cells overexpressing MDM2, and similar results were observed in Saos-2 cells transfected

with ER α and MDM2 expression plasmids and an ERE reporter construct (Saji *et al.* 2001). In this study, we first examined the effects of endogenous MDM2 on E₂-induced transactivation in ZR-75 breast cancer cells transfected with pERE₃ (Fig. 1A) or pSP1₃ (Fig. 1B) constructs containing three tandem EREs or consensus GC-rich SP1 binding sites linked to the luciferase gene respectively. These constructs in which ER α or ER α /SP1 activate their respective promoters represent two of the major genomic pathways of estrogen action in breast cancer cells (Hall *et al.* 2001, Safe & Kim 2004). The results show that siRNA for MDM2 significantly decreased E₂-induced transactivation in cells transfected with pERE₃ or pSP1₃ compared with cells transfected with siCT (nonspecific oligonucleotide) or untransfected cells. As a positive control, siGL2 (siRNA

Figure 1 MDM2 knockdown inhibits estrogen-induced ER α and ER α /SP-mediated transactivation. MCF-7 cells were transfected with pERE₃ (A) or pSP1₃ (B) and ZR-75 cells were transfected with pERE₃ (C) or pSP1₃ (D) and various (or no) oligonucleotides and treated with DMSO or 10 nM E₂. Luciferase activity was determined as described in the section 'Materials and methods'. Significant ($P < 0.05$) induction by E₂ (*) and inhibition by iMDM2 or iGL2 (**) are indicated. Results are expressed as means $\pm$ S.E.M. for at least three separate determinations for each treatment group. Minimal activity was observed in cells transfected with the empty vector, and treatment with DMSO or E₂ did not induce activity. (E) MDM2 knockdown. MCF-7 cells were transfected with a nonspecific (siCT) or siMDM2 oligonucleotide, and whole cell lysates were analyzed by western blots as described in the section 'Materials and methods'. MCF-7 cells were used for whole cell lysate analysis due to higher transfection efficiency compared to ZR-75 cells.

for luciferase) also decreased luciferase activity. Endogenous luciferase activity in cells transfected with pSP1₃ was not affected by siMDM2, suggesting that coactivation of ER α /specificity protein (SP) may be due to interactions of MDM2 with ER α , not with Sp proteins. Figure 1C and D show that MDM2 knockdown (siMDM2) inhibited E₂-induced transactivation in ZR-75 cells transfected with the pERE₃ or pSP1₃ constructs; similar results were observed in ZR-75 cells transfected with E₂-responsive GC-rich constructs containing promoter inserts from the *E2F1* and *CAD* genes (Wang *et al.* 1999, Khan *et al.* 2003, Ngwenya & Safe 2003; data not shown). Moreover, in a mammalian two-hybrid assay in ZR-75 cells, we did not observe SP1-MDM2 interactions (data not shown). Results in Fig. 1E show that siMDM2 decreased siMDM2 protein expression in MCF-7 cells, increased p53 protein expression, and did not affect the levels of SP1 protein.

The effects of overexpression of MDM2 on coactivation of ER α and ER α /SP were investigated in MCF-7 cells transfected with pERE₃ (Fig. 2A) or pSP1₃ (Fig. 2B), and the results showed that MDM2 significantly enhanced ER α and ER α /SP-mediated transactivation and similar results were observed in ZR-75 cells (data not shown). Coactivation of ER α by MDM2 was further investigated in MCF-7 (Fig. 2C) and ZR-75 (Fig. 2D) cells transfected with MDM2, a GAL4-ER α chimeric protein (pMER), and a construct (GAL4-luc) containing five tandem GAL4 response elements. The results show that E₂ significantly induced transactivation in both cell lines and this response was further enhanced by MDM2 expression. Moreover, E₂-induced transactivation in MCF-7 cells transfected with pMER and GAL4-luc was significantly decreased after cotransfection with siMDM2 or siGL2 that knocks down luciferase (Fig. 2E), confirming that MDM2 coactivates ER α -mediated transactivation.

MDM2 interacts with ER α

It was previously reported that in a mammalian two-hybrid assay in Saos-2 cells using pM-ER α and VP-MDM2, E₂ induced transactivation (interaction); however, in GST pull-down studies ER α interacted with MDM2 in the presence or absence of ligand (Saji *et al.* 2001). Results in Fig. 3A show that in mammalian two-hybrid assays in ZR-75 cells, there was increased transactivation in cells transfected with pM-MDM2 and VP-ER α compared with cells transfected with pM-MDM2 and VP and this interaction did not require the addition of E₂. Moreover, in coimmunoprecipitation experiments with *in vitro* expressed ³⁵S-labeled ER α and MDM2 (Xpress-tagged), both proteins interacted in the presence or absence of E₂ (Fig. 3B). The interactions of ER α and MDM2 in living cells were also investigated by FRET in cells transfected with a

Figure 2 MDM2 coactivates ER α and ER α /SP-dependent transactivation. MCF-7 cells were treated with DMSO or E₂, transfected with pERE₃ (A) or pSP1₃ (B) and different amounts of MDM2 expression plasmid, and luciferase activity was determined as described in the section 'Materials and methods'. The effects of MDM2 expression in MCF-7 (C) and ZR-75 (D) cells or MDM2 knockdown in MCF-7 (E) cells on activation of pM-ER α . The cells were treated with DMSO or 10 nM E₂, transfected with pMER and MDM2 expression plasmid, a GAL4-luc reporter construct, and oligonucleotides (as indicated); luciferase activation was determined as outlined in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for at least three replicate determinations for each treatment group as significant ($P < 0.05$) coactivation by MDM2 (*) and inhibition by siMDM2 or siGL2 (**) are indicated.

CFP-MDM2 construct and a YFP-ER α construct. In preliminary experiments, we showed that similar to MDM2, ECFP-MDM2 also enhanced E₂-dependent transactivation in ZR-75 cells transfected with pM-ER α /GAL4-luc (Fig. 3C). FRET analysis was determined in MCF-7 cells transfected with CFP-MDM2 and YFP-ER α (Fig. 3D). The FRET efficiencies obtained are illustrated in Fig. 3E and show that E₂ significantly enhanced this response, indicating that although both proteins directly interact in the absence of E₂, treatment with hormone clearly enhances this interaction and facilitates the energy transfer between

the CFP and YFP moieties in both proteins. As a positive control for this experiment, we also show that E₂ enhances YFP-ER α interactions with CFP-SP1 as previously reported (Kim *et al.* 2005). There was clearly a parallel between the significant effects of E₂ on FRET efficiencies associated with YFP-ER α -CFP-SP1 and YFP-ER α -CFP-MDM2 and the E₂-independent interaction of ER α with both SP1 (Kim *et al.* 2005) and MDM2 (Fig. 3A and B) in coimmunoprecipitation experiments.

MDM2 contains several domains that interact with other proteins and also a zinc finger and a C-terminal RING finger domain that functions as an E3-ubiquitin ligase (Ashcroft *et al.* 1999, Kubbutat *et al.* 1999). We initially examined the interactions of wild-type and deletion variants of MDM2 (Xpress-tagged) with ER α , and Fig. 4A illustrates the electrophoretic mobilities and interactions between ³⁵S-labeled ER and ³⁵S-labeled wild-type MDM2 and variants expressing amino acids 1–342 (MDM2(1–342 aa)), 134–342 (MDM2(134–342 aa)), and 134–490 (MDM2(134–490 aa)). Coimmunoprecipitation experiments showed that ER α interacted with wild-type MDM2 (lane 7), MDM2 (1–342 aa) (lane 8), MDM2 (134–490 aa) (lane 10) but not with MDM2 (134–342 aa) (lane 9). Lanes 1–6 illustrate the ³⁵S-labeled proteins alone. Thus, ER α interacts with both C- and N-terminal domains of MDM2 but not with the 134–342 aa region, which binds CBP/p300 (Grossman *et al.* 1998). In contrast, coactivation studies in ZR-75 cells transfected with pM-ER α showed that only wild-type, but not the deletion variants of MDM2, coactivated ER α (Fig. 4B). These results suggest that multiple regions of MDM2 are required for coactivation of ER α .

MDM2 enhances interactions of ER α with steroid receptor coactivators

Steroid receptor coactivators (SRCs), mediator proteins, and p300 associate with ER as complexes that interact cyclically with E₂-responsive gene promoters, and MDM2 has been identified as a component of these complexes (Metivier *et al.* 2003, Reid *et al.* 2003). The role of MDM2 and its interactions with coactivators has been further investigated in mammalian two-hybrid assays using coactivator-GAL4 chimeras (pM-coactivators), VP-ER α , and GAL4-luc in ZR-75 cells. In cells transfected with pMGRIPwt, VP-ER α and GAL4-luc treatment with E₂ induced transactivation; however, E₂-dependent interactions were significantly inhibited in cells cotransfected with siMDM2, suggesting that interactions of GRIP (SRC-2) and ER α are mediated, in part, by MDM2 (Fig. 5A). Interactions of GRIP and MDM2 were also investigated in a mammalian two-hybrid assay in ZR-75 cells transfected with pMGRIP/GAL4-luc and VP-MDM2, and the results

Figure 3 Interactions of MDM2 and ERα. (A) Mammalian two-hybrid assay. Cells were transfected with various constructs and a GAL4-luc reporter gene and luciferase activity was determined as described in the section 'Materials and methods'. (B) Coimmunoprecipitation of MDM2 and ERα. [³⁵S]ERα and [³⁵S]MDM2 (Xpress-tagged) were *in vitro* expressed, treated with or without E₂, and coimmunoprecipitated with Xpress antibodies and then analyzed by western blots as described in the section 'Materials and methods'. (C) Coactivation of pMER by MDM2. ZR-75 cells were treated with DMSO or 10 nM E₂ transfected with pMER/GAL4-luc and MDM2 or ECFP-MDM2, and luciferase activity was determined as outlined in the section 'Materials and methods'. (D) MDM2:ERα interactions – FRET analysis. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with CFP-MDM2 or YFP-ERα expression plasmids, and E₂-dependent interactions were determined by FRET as described in the section 'Materials and methods'. (E) FRET efficiencies. ZR-75 cells were treated with DMSO or 10 nM E₂ and transfected with various constructs, and FRET efficiencies were determined as described in the section 'Materials and methods'. The results of transfection studies (A, C, and E) are means ± S.E.M. for at least three replicate determinations for each treatment group, and significant (*P* < 0.05) induction is indicated (*). Full colour version of this figure available via <http://dx.doi.org/10.1677/JME-10-0110>.

show that MDM2 and GRIP do not interact in the presence or absence of E₂ (Fig. 5B). However, after cotransfection with ERα, there was a significant increase in transactivation, which was observed in the absence or presence of E₂ but was more pronounced in the former

case. These results suggest that, although GRIP and MDM2 do not exhibit binding in a two-hybrid assay, the expression of ERα significantly enhanced interactions between GRIP and MDM2. ER-coactivator interactions are dependent, in part, on interactions between

Figure 4 Physical and functional interaction of ER α with wild-type and variant MDM2. (A) *In vitro* interactions. Various [³⁵S]-labeled proteins were *in vitro* expressed, coimmunoprecipitated, and analyzed by western blots as outlined in the section 'Materials and methods', and only wild-type and variant MDM2 were Xpress-tagged. (B) Coactivation of ER α by wild-type and deletion mutant forms of MDM2. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with pMER/GAL4-luc and various wild-type and deletion mutant MDM2 expression plasmids, and luciferase activity was determined as outlined in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for at least three replicate determinations for each treatment group, and significant ($P < 0.05$) coactivation is indicated (*).

NR-box (LXXLL) motifs in coactivators (Torchia *et al.* 1997, Voegel *et al.* 1998) with ER α , and Fig. 5C shows that E₂ induces transactivation in ZR-75 cells transfected with VP-ER α and pMGRIP(LXXLL)/GAL4-luc where pMGRIP(LXXLL) is a chimera containing GAL4 fused to aa629–760 from GRIP/SRC-2, which contains an LXXLL motif. E₂-dependent interactions of ER α and GRIP(LXXLL) in the mammalian two-hybrid assay were inhibited after cotransfection with siMDM2, suggesting that MDM2 facilitates ER α interactions with the NR-box motif of GRIP. pMGRIP(LXXLL) did not interact with VP-MDM2 in a two-hybrid assay; however, cotransfection with ER α in the presence or absence of E₂ enhanced transactivation (Fig. 5D).

These results suggest that ER α enhances MDM2 interactions with the NR-box motif of GRIP.

The role of MDM2 in the interaction of ER α with SRC-1 and SRC-3 (AIB-1) was also investigated in mammalian two-hybrid assays in ZR-75 cells (Fig. 6), and the results were similar to those observed for ER α and GRIP. E₂ induced transactivation in cells transfected with pMSRC-1/GAL4-luc plus VP-ER α (Fig. 6A) or pMAIB-1/GAL4-luc plus VP-ER α (Fig. 6B). Cotransfection with siMDM2 inhibited basal and induced activity, and the inhibition was most pronounced for AIB-1-ER interactions. Interactions of pMSRC-1 and VP-MDM2 (Fig. 6C) or pMAIB-1 and VP-MDM2 (Fig. 6D) were not observed in mammalian two-hybrid assays; however, cotransfection with ER α significantly enhanced transactivation in the absence or presence of E₂. The hormone-induced response was more pronounced with pMAIB-1 compared to pMSRC-1; moreover, E₂ decreased transactivation in ZR-75 cells transfected with pMSRC-1, VP16-MDM2 and ER α , suggesting that liganded ER α may inhibit SRC-1-MDM2 interactions. These results demonstrate that although MDM2 does not interact with SRCs, this protein plays a key role in enhancing ER α interactions with the SRC coactivators. Results in Fig. 6E demonstrate that E₂ also induces transactivation in ZR-75 cells transfected pMp300/GAL4-luc and VP-ER; however, siMDM2 slightly enhances both basal and E₂-induced activity. These results demonstrate the specificity of the SRC-ER α -MDM2 compared to that observed for p300-ER α -MDM2 interactions where MDM2 plays a key role in coactivator ER α interactions but not p300-ER α interactions. The 'constitutive' inhibitory effect may be due to the competitive binding of both ER α and MDM2 to p300 (Hanstein *et al.* 1996, Grossman *et al.* 1998).

MDM2 enhances E₂-dependent activation of pS2 and E2F1 and cell proliferation

The functional effects of MDM2 on hormone-induced gene expression were investigated in p53-expressing ZR-75 cells and T47D cells that do not express functional p53. In ZR-75 (Fig. 7A) and T47D (Fig. 7B) cells transfected with siMDM2, induction of E2F1 protein expression was decreased after the loss of MDM2. The role of MDM2 in hormone-induced expression of E2F1 and pS2 mRNA levels in ZR-75 (Fig. 7C) and T47D (Fig. 7D) cells was also determined, and the hormone-induced responses were significantly decreased in cells transfected with siMDM2. Moreover, using a similar approach, knockdown of MDM2 by RNA interference in T47D cells decreased induction of CAD and cyclin D1 by E₂ (data not shown). Since p53 inhibits estrogen responsiveness, it is possible that the loss of hormone-induced transactivation in breast cancer cells transfected with siMDM2 may be due, in part, to activation of

Figure 5 The effects of MDM2 on coactivation of ER α by GRIP (SRC-2). ZR-75 cells were treated with DMSO or 10 nM E₂, and transfected with pMGRIPwt/VP-ER α and iCT or iMDM2 oligonucleotides (A) or pMGRIPwt/VP16-MDM2, empty vectors and hER α (B), and luciferase activity was determined as described in the section 'Materials and methods'. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with pMGRIP(LXXLL)/VP-ER α and iCT or iMDM2 oligonucleotides (C) or pMGRIP(LXXLL)/VP16-MDM2, empty vectors and ER α (D), and luciferase activity was determined as described in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for at least three replicate determinations for each treatment group, and significantly ($P < 0.05$) enhanced interactions by ER α (*) and decreased activity by iMDM2 (**) are indicated.

p53. We also compared the effects of hormone-induced transactivation in MCF-7 cells transfected with sip53, siMDM2, and their combination. E₂ induced *pS2* and *E2F1* gene expression in MCF-7 cells treated with E₂ and this response was decreased after cotransfection with siMDM2 or siMDM2 plus sip53, but unaffected by sip53 alone (data not shown). Similar results were observed for induction of luciferase activity in cells transfected with pSP1₃ and pERE₃ (data not shown), demonstrating that the effects of siMDM2 were p53 independent. Nutlin-3 is an MDM2 antagonist, which dissociates the MDM2–p53 complex, resulting in activation of p53 (Vassilev *et al.* 2004). In T47D cells that do not express wild-type p53, addition of Nutlin-3 did not affect induction of E2F1 by E₂ (Fig. 7E). In contrast, Nutlin-3 significantly decreased basal and E₂-inducible E2F1 in ZR-75 cells that express wild-type p53 (Fig. 7D), demonstrating that inhibition of MDM2, like knockdown of MDM2 (Figs 1 and 2), decreased hormonal activation of E2F1. The effects of MDM2 knockdown on basal and E₂-induced proliferation were also

investigated in MCF-7 and ZR-75 cells (Fig. 7F). The results show that loss of MDM2 in these cells decreased both basal and hormone-induced cell growth after 96 h, further demonstrating the critical role for MDM2 in both cell lines. These results confirm the important role of MDM2 as a coregulator of hormone-induced gene expression in breast cancer cells.

Discussion

Coactivators and other coregulatory proteins play a critical role in hormone receptor-dependent gene expression, and these nuclear proteins are essential factors for ligand-induced transcriptional activation (Blanco *et al.* 1998, O'Malley 2007). Initial studies describing coactivation of nuclear receptors by SRCs demonstrated several essential features of coactivator function. These included identification of NR-boxes required for specific coactivator–receptor interactions (Torchia *et al.* 1997, Voegel *et al.* 1998), histone acetyltransferase activity of some SRCs, which facilitates interaction of receptor–coregulatory complexes with promoter DNA, and interactions of coactivators with multiple domains of nuclear receptors and with other nuclear cofactors (Blanco *et al.* 1998, O'Malley 2007). This complexity associated with SRCs has been further magnified by ongoing studies that have identified many other classes of coactivators, which manifest their activities through ATP-dependent chromatin modeling, histone methylation, or modification of receptors through ubiquitination or sumoylation (Blanco *et al.* 1998, O'Malley 2007, O'Malley & Kumar 2009).

The interactions of different functional classes of nuclear factors in ER α -mediated transcriptional activation have been extensively investigated in chromatin immunoprecipitation (ChIP) assays, which demonstrate an ordered cycling of distinct cofactor/ER α complexes on and off the E₂-responsive *pS2* gene promoter (Shang *et al.* 2000, Burakov *et al.* 2002, Metivier *et al.* 2003, Reid *et al.* 2003). MDM2, which exhibits E3-ubiquitin ligase activity, is involved in this cycling process, and previous studies have shown that MDM2 overexpression coactivates ER α -dependent transactivation in cells transfected with ERE-promoter constructs (Saji *et al.* 2001). Research in this laboratory and others have demonstrated that E₂ also activates genes in breast cancer cells through ER α /SP interactions with GC-rich promoters (O'Malley 2007), and we have been investigating the coactivation of ER α and ER α /SP in breast cancer cells transfected with pERE₃ and pSP1₃ respectively (Kim *et al.* 2003, Wu *et al.* 2004, Lee *et al.* 2005, Lee & Safe 2007). Vitamin D interacting protein 150 (DRIP150) is a mediator complex protein (Koh *et al.* 2002, Kouzmenko *et al.* 2004), which coactivates ER α and ER α /SP1, and this

Figure 6 Effects of MDM2 on coactivation of ER α by other coactivators and p300. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with pMSRC-1/VP-ER α (A) or pMAIB-1/VP-ER α (B), GAL4-luc and siCT or siMDM2 oligonucleotides, and luciferase activity was determined as outlined in the section 'Materials and methods'. The effects of ER α on MDM2 coactivator interactions. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with pMSRC-1/VP-MDM2 or pMAIB-1/VP-MDM2, empty vectors or ER α and GAL4-luc, and luciferase activity was determined as described in the section 'Materials and methods'. (E) The effect of MDM2 knockdown on ER α -p300 interactions. ZR-75 cells were treated with DMSO or 10 nM E₂, transfected with pMp300/VP-ER α and GAL-luc, and luciferase activity was determined as outlined in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for at least three replicate determinations for each treatment group and significantly ($P < 0.05$) enhanced activity after transfections with ER α (*) and decreased activity after transfection with siMDM2 (**) are indicated.

involves an α -helical NIFSEVRVYN (amino acids 795–804) motif within a 23 amino acid sequence (789–811) in the central region of DRIP150 that does not contain an LXXLL box (Lee *et al.* 2005, Lee & Safe 2007). DRIP150 had minimal effects on SP-dependent transactivation and coactivated ER α and ER α /SP1 primarily through interactions with ER α (Lee & Safe 2007). In this study, we demonstrate that E₂-induced transactivation in breast cancer cells transfected with pSP1₃ or pERE₃ was significantly inhibited by knockdown of MDM2 by RNA interference (siMDM2) (Fig. 1A and B), and overexpression of Mdm2 also

enhanced transactivation in cells transfected with pSP1₃ or pERE₃ constructs (Fig. 2A and B). We also observed that in ZR-75 and T47D cells transfected with siMDM2, there was a significant decrease in hormone-induced protein and mRNA levels (Fig. 7), demonstrating a role for MDM2 in E₂-induced gene expression. These results confirm coactivation of ER α by MDM2 as previously reported (Saji *et al.* 2001) and also show that MDM2 coactivates ER α /SP1. MDM2 did not interact with SP1 and knockdown or overexpression of MDM2 did not affect SP-dependent transactivation (Figs 1A and B and 2A and C), suggesting that coactivation of ER α and ER α /SP1 is primarily associated with direct interactions between MDM2 and ER α .

MDM2 interacts with ER α in the presence or absence of E₂ (Fig. 3A and B) and E₂ also enhances ER α -MDM2 interactions in living cells as determined by FRET analysis (Fig. 3D and E). It is clear from ChIP assays that ER α , MDM2, and other nuclear coregulatory proteins cycle on and off E₂-responsive gene promoters in breast cancer cells, and there is also evidence that specific subsets of coactivators may be selectively recruited to the pS2 promoter (Metivier *et al.* 2003). Since constitutively expressed and transiently overexpressed MDM2 activated ER α and ER α /SP1, it is possible that this protein may also act in concert with other nuclear cofactors such as the SRCs. Previous studies have demonstrated coactivation of ER α by SRCs (Blanco *et al.* 1998, Vassilev *et al.* 2004, O'Malley 2007) and corecruitment of MDM2 and SRCs to E₂-responsive gene promoters and, therefore, we hypothesized that MDM2 acts, in part, through facilitating SRC-ER α interactions. Results in Figs 5 and 6 demonstrate that interactions of pMSRCs with VP-ER α are E₂ dependent, and similar results were observed with interactions of VP-ER with the GRIP1 LXXLL box (GAL4-GRIP(LXXLL)) (Fig. 5C). These hormone-dependent ER-SRC interactions were not surprising; however, using RNA interference with siMDM2, it was evident that MDM2 facilitated ER α -SRC (Figs 5A and 6A, and C) but not ER α -p300 (Fig. 6E) interactions in a mammalian two-hybrid assay. Moreover, it was also apparent in mammalian two-hybrid assays in which cells were transfected with pMSRC and VP16-MDM2 that MDM2 did not directly interact with coactivators unless ER α was also overexpressed, and this resulted in increased transactivation in the presence or absence of E₂ (Figs 5B and 6B and D).

These results suggest a model for MDM2 coactivation of ER α or ER α /SP1 in which MDM2 acts alone or in combination with SRCs to enhance transactivation. This resembles, in part, a similar model proposed for β -catenin, which enhances nuclear receptor or transcription factor-mediated transactivation alone and in combination with other coactivators (Koh *et al.* 2002, Kouzmenko *et al.* 2004, Li *et al.* 2004, Yang *et al.* 2006).

Figure 7 MDM2 regulates ER α - and E₂-dependent genes and responses in breast cancer cells. The effects of siMDM2 on E2F1 protein levels in ZR-75 (A) and T47D (B) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with 10 nM E₂ for 0, 6, or 12 h, and whole cell lysates were analyzed for E2F1 and β -actin (loading control) by western blots as described in the section 'Materials and methods'. The effects of siMDM2 on E2F1 and pS2 mRNA levels in ZR-75 (C) and T47D (D) cells. Cells were transfected with siCT (nonspecific) or siMDM2, treated with DMSO or 10 nM E₂ for the indicated times, and mRNA levels were determined by real-time PCR as described in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for three replicate determinations and significant ($P < 0.05$) induction by E₂ (*) and inhibition by siMDM2 (**) are indicated. (E) The effects of Nutlin. T47D or ZR-75 cells were treated with DMSO or 10 nM E₂ in the presence or absence of 5 μ M Nutlin and analyzed for E2F1 and β -actin (loading control) by western blots. (F) siMDM2 inhibits growth and hormone-induced cell proliferation. MCF-7 or ZR-75 cells were transfected with siCT or siMDM2, treated with DMSO or 10 nM E₂, and cells were counted at various time points as described in the section 'Materials and methods'. The results are expressed as means $\pm$ S.E.M. for three replicate determinations and significant induction by E₂ (compared to DMSO) (*) and inhibition by siMDM2 (**) are indicated.

For example, β -catenin enhanced interactions between LEF1 (GAL4-LEF1) and GRIP1 (VP-GRIP), and this was primarily due to coactivation and interactions of β -catenin with LEF1 but not with GRIP1. Similarly, this study shows that MDM2 enhanced interactions between ER α and SRCs, and this was primarily associated with coactivation and interactions with ER α since MDM2 and SRCs did not interact. The cooperative coactivation of nuclear receptors by coactivators and other nuclear factors is highly variable. For example, CARM1 and p300 enhanced GRIP1-dependent coactivation of ER α and the former proteins interact with GRIP1 but not with ER α (Chen *et al.* 2000). In contrast, the model for coactivation of ER α and ER α /SP1 by SRCs and MDM2 primarily involves MDM2 interactions with ER α and not with SRCs.

Current studies are investigating the role of MDM2 in regulating expression of E₂-responsive genes with ERE and GC-rich promoters and determining their cyclical interactions with gene promoters and other coactivators using ChIP assays. Our results clearly demonstrate that MDM2 enhances ER-dependent transactivation and cell proliferation (Fig. 7), and in transactivation assays, the loss of hormone responsiveness in cells transfected with siMDM2 was p53 independent (data not shown). Cotransfection of cells with siMDM2 alone or siMDM2 plus sip53 gave similar results, whereas knockdown of p53 alone (sip53) slightly enhanced hormone-induced transactivation, and this was consistent with a recent study (Akaogi *et al.* 2009) and a report showing that p53 decreases hormone-induced transactivation (Liu *et al.* 1999). In breast cancer, the potential prognostic significance of MDM2 or an MDM2 promoter polymorphism (SNP309) that enhances MDM2 expression has been inconsistent (Wilkening *et al.* 2007). However, examination of the publically available Netherlands Kanker Instituut (NKI) gene expression data from ER-positive breast cancer patients (van de Vijver *et al.* 2002) shows that low-MDM2 levels predict a higher overall and relapse-free survival compared with patients with high-MDM2 levels (data not shown) and this observation is consistent with the results of this study showing the critical role of MDM2 in hormone-induced gene expression and growth of ER-positive breast cancer cells, suggesting that MDM2 inhibitors may be efficacious for treatment of ER-positive breast cancer patients. However, it should also be noted that the loss of MDM2 and the decreased MCF-7 and ZR-75 cell proliferation (Fig. 7F) may also be due to the parallel activation of p53 after MDM2 knockdown.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research was supported by the National Institutes of Health and is gratefully acknowledged (ES04917).

References

- Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, Kimura K & Yanagisawa J 2009 KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ER α . *Oncogene* **28** 2894–2902. (doi:10.1038/onc.2009.151)
- Ashcroft M, Kubbutat MH & Vousden KH 1999 Regulation of p53 function and stability by phosphorylation. *Molecular and Cellular Biology* **19** 1751–1758.
- Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y & Ozato K 1998 The histone acetylase PCAF is a nuclear receptor coactivator. *Genes and Development* **12** 1638–1651. (doi:10.1101/gad.12.11.1638)
- Brooks CL & Gu W 2006 p53 ubiquitination: Mdm2 and beyond. *Molecular Cell* **21** 307–315. (doi:10.1016/j.molcel.2006.01.020)
- Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N & Albitar M 1996 Abnormal expression of MDM-2 in breast carcinomas. *Breast Cancer Research and Treatment* **37** 179–188. (doi:10.1007/BF01806499)
- Burakov D, Crofts LA, Chang CPB & Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes *in vivo* by estrogen receptor. *Journal of Biological Chemistry* **277** 14359–14362. (doi:10.1074/jbc.C200099200)
- Cahilly-Snyder L, Yang-Feng T, Francke U & George DL 1987 Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. *Somatic Cell and Molecular Genetics* **13** 235–244. (doi:10.1007/BF01535205)
- Chen DG, Huang SM & Stallcup MR 2000 Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. *Journal of Biological Chemistry* **275** 40810–40816. (doi:10.1074/jbc.M005459200)
- Fakhrazadeh SS, Trusko SP & George DL 1991 Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. *EMBO Journal* **10** 1565–1569.
- Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM & Livingston DM 1998 p300/MDM2 complexes participate in MDM2-mediated p53 degradation. *Molecular Cell* **2** 405–415. (doi:10.1016/S1097-2765(00)80140-9)
- Hall JM, Couse JF & Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. *Journal of Biological Chemistry* **276** 36869–36872. (doi:10.1074/jbc.R100029200)
- Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R & Brown N 1996 p300 is a component of an estrogen receptor coactivator complex. *PNAS* **93** 11540–11545. (doi:10.1073/pnas.93.21.11540)
- Hori M, Shimazaki J, Inagawa S, Itabashi M & Hori M 2002 Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor α and lack of MDM2 mRNA splice variants in human breast cancer. *Breast Cancer Research and Treatment* **71** 77–83. (doi:10.1023/A:1013350419426)
- Hsieh JK, Chan FS, O'Connor DJ, Mitnacht S, Zhong S & Lu X 1999 RB regulates the stability and the apoptotic function of p53 via MDM2. *Molecular Cell* **3** 181–193. (doi:10.1016/S1097-2765(00)80309-3)
- Jones SN, Roe AE, Donehower LA & Bradley A 1995 Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. *Nature* **378** 206–208. (doi:10.1038/378206a0)
- Khan S, Abdelrahim M, Samudio I & Safe S 2003 Estrogen receptor/Sp1 complexes are required for induction of *cad* gene expression by 17 β -estradiol in breast cancer cells. *Endocrinology* **144** 2325–2335. (doi:10.1210/en.2002-0149)

- Kim K, Nguyen T, Saville B & Safe S 2003 Domains of estrogen receptor α (ER α) required for ER α /Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. *Molecular Endocrinology* **17** 804–817. (doi:10.1210/me.2002-0406)
- Kim K, Barhoumi R, Burghardt R & Safe S 2005 Analysis of estrogen receptor α -Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. *Molecular Endocrinology* **19** 843–854. (doi:10.1210/me.2004-0326)
- Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM & Stallcup MR 2002 Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and β -catenin with two different classes of DNA-binding transcriptional activators. *Journal of Biological Chemistry* **277** 26031–26035. (doi:10.1074/jbc.M110865200)
- Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A & Thomas-Tsagli E 1997 MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. *British Journal of Cancer* **75** 1269–1278.
- Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T *et al.* 2004 Wnt/ β -catenin and estrogen signaling converge *in vivo*. *Journal of Biological Chemistry* **279** 40255–40258. (doi:10.1074/jbc.C400331200)
- Kubbutat MH, Ludwig RL, Levine AJ & Vousden KH 1999 Analysis of the degradation function of Mdm2. *Cell Growth and Differentiation* **10** 87–92.
- Lee J & Safe S 2007 Coactivation of estrogen receptor α (ER α)/Sp1 by vitamin D receptor interacting protein 150 (DRIP150). *Archives of Biochemistry and Biophysics* **461** 200–210. (doi:10.1016/j.abb.2006.12.030)
- Lee JE, Kim K, Sacchetti JC, Smith CV & Safe S 2005 DRIP150 coactivation of estrogen receptor α in ZR-75 breast cancer cells is independent of LXXLL motifs. *Journal of Biological Chemistry* **280** 8819–8830. (doi:10.1074/jbc.M413184200)
- Levav-Cohen Y, Haupt S & Haupt Y 2005 Mdm2 in growth signaling and cancer. *Growth Factors* **23** 183–192. (doi:10.1080/08977190500196218)
- Leveillard T & Wasylyk B 1997 The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. *Journal of Biological Chemistry* **272** 30651–30661. (doi:10.1074/jbc.272.49.30651)
- Li H, Kim JH, Koh SS & Stallcup MR 2004 Synergistic effects of coactivators GRIP1 and β -catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. *Journal of Biological Chemistry* **279** 4212–4220. (doi:10.1074/jbc.M311374200)
- Liu G, Schwartz JA & Brooks SC 1999 p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. *Biochemical and Biophysical Research Communications* **264** 359–364. (doi:10.1006/bbrc.1999.1525)
- Liu G, Schwartz JA & Brooks SC 2000 Estrogen receptor protects p53 from deactivation by human double minute-2. *Cancer Research* **60** 1810–1814.
- Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S & Press MF 2001 Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. *Cancer Research* **61** 3212–3219.
- Martin K, Trouche D, Hagemeyer C, Sorensen TS, La Thangue NB & Kouzarides T 1995 Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. *Nature* **375** 691–694. (doi:10.1038/375691a0)
- Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M & Gannon F 2003 Estrogen receptor- α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* **115** 751–763. (doi:10.1016/S0092-8674(03)00934-6)
- Momand J, Zambetti GP, Olson DC, George D & Levine AJ 1992 The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell* **69** 1237–1245. (doi:10.1016/0092-8674(92)90644-R)
- Montes de Oca Luna R, Wagner DS & Lozano G 1995 Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. *Nature* **378** 203–206. (doi:10.1038/378203a0)
- Ngwenya S & Safe S 2003 Cell context-dependent differences in the induction of E2F-1 gene expression by 17 β -estradiol in MCF-7 and ZR-75 cells. *Endocrinology* **144** 1675–1685. (doi:10.1210/en.2002-0009)
- O'Malley BW 2007 Coregulators: from whence came these "master genes". *Molecular Endocrinology* **21** 1009–1013. (doi:10.1210/me.2007-0012)
- O'Malley BW & Kumar R 2009 Nuclear receptor coregulators in cancer biology. *Cancer Research* **69** 8217–8222. (doi:10.1158/0008-5472.CAN-09-2223)
- Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V & Burkert W 1997 Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. *Journal of Neuro-Oncology* **35** 13–28. (doi:10.1023/A:1005841520514)
- Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J & Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ER α on responsive promoters is an integral feature of estrogen signaling. *Molecular Cell* **11** 695–707. (doi:10.1016/S1097-2765(03)00090-X)
- de Rozieres S, Maya R, Oren M & Lozano G 2000 The loss of mdm2 induces p53-mediated apoptosis. *Oncogene* **19** 1691–1697. (doi:10.1038/sj.onc.1203468)
- Safe S & Kim K 2004 Nuclear receptor-mediated transactivation through interaction with Sp proteins. *Progress in Nucleic Acid Research and Molecular Biology* **77** 1–36. (doi:10.1016/S0079-6603(04)77001-4)
- Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S & Hayashi S 2001 MDM2 enhances the function of estrogen receptor α in human breast cancer cells. *Biochemical and Biophysical Research Communications* **281** 259–265. (doi:10.1006/bbrc.2001.4339)
- Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP & Bamberg M 2000 Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. *Journal of Neuro-Oncology* **49** 197–203. (doi:10.1023/A:1006410702284)
- Sengupta S & Wasylyk B 2004 Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. *Annals of the New York Academy of Sciences* **1024** 54–71. (doi:10.1196/annals.1321.005)
- Shang Y, Hu X, DiRenzo J, Lazar MA & Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* **103** 843–852. (doi:10.1016/S0092-8674(00)00188-4)
- Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK & Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. *Nature* **387** 677–684. (doi:10.1038/42652)
- Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C *et al.* 2004 *In vivo* activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* **303** 844–848. (doi:10.1126/science.1092472)
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ *et al.* 2002 A gene-expression signature as a predictor of survival in breast cancer. *New England Journal of Medicine* **347** 1999–2009. (doi:10.1056/NEJMoa021967)
- Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P & Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. *EMBO Journal* **17** 507–519. (doi:10.1093/emboj/17.2.507)

- Wang W, Dong L, Saville B & Safe S 1999 Transcriptional activation of E2F1 gene expression by 17 β -estradiol in MCF-7 cells is regulated by NF-Y – Sp1/estrogen receptor interactions. *Molecular Endocrinology* **13** 1373–1387. (doi:10.1210/me.13.8.1373)
- Wilkening S, Bermejo JL & Hemminki K 2007 MDM2 SNP309 and cancer risk: a combined analysis. *Carcinogenesis* **28** 2262–2267. (doi:10.1093/carcin/bgm191)
- Wu Q, Burghardt R & Safe S 2004 Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor α (ER α) involves multiple domains of both proteins. *Journal of Biological Chemistry* **279** 53602–53612. (doi:10.1074/jbc.M409778200)
- Yang CK, Kim JH, Li H & Stallcup MR 2006 Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with β -catenin or GRIP1. *Journal of Biological Chemistry* **281** 3389–3397. (doi:10.1074/jbc.M510403200)

Received in final form 8 December 2010

Accepted 17 December 2010

Made available online as an Accepted Preprint 17 December 2010